These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10811502)

  • 1. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.
    Caponigro F; Comella P; Budillon A; Bryce J; Avallone A; De Rosa V; Ionna F; Comella G
    Ann Oncol; 2000 Mar; 11(3):339-42. PubMed ID: 10811502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
    Janinis J; Stathopoulos GP; Nikolaidis P; Kalofonos HP; Kalogera-Fountzila A; Samantas E; Aravantinos G; Anagnostopoulos A; Tolis C; Makatsoris T; Rigatos SK; Bafaloukos D; Dimopoulos MA; Daniilidis J; Fountzilas G
    Anticancer Drugs; 2004 Jun; 15(5):479-87. PubMed ID: 15166622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.
    Samantas E; Kalofonos H; Linardou H; Nicolaides C; Mylonakis N; Fountzilas G; Kosmidis P; Skarlos D
    Ann Oncol; 2000 Nov; 11(11):1395-7. PubMed ID: 11142478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer.
    Koukourakis MI; Koukouraki S; Giatromanolaki A; Archimandritis SC; Skarlatos J; Beroukas K; Bizakis JG; Retalis G; Karkavitsas N; Helidonis ES
    J Clin Oncol; 1999 Nov; 17(11):3512-21. PubMed ID: 10550149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.
    Ghesquières H; Faivre S; Djafari L; Pautier P; Lhommé C; Lozahic S; Djazouli K; Armand JP; Raymond E
    Invest New Drugs; 2006 Sep; 24(5):413-21. PubMed ID: 16763786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck.
    Harrington KJ; Lewanski C; Northcote AD; Whittaker J; Peters AM; Vile RG; Stewart JS
    Eur J Cancer; 2001 Nov; 37(16):2015-22. PubMed ID: 11597379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
    Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D
    Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
    Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V
    Eur J Cancer; 2002 Oct; 38(15):1992-7. PubMed ID: 12376203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck.
    Faivre S; Alsabe H; Djafari L; Janot F; Julieron M; Domenge C; Djazouli K; Armand JP; Luboinski B; Raymond E
    Eur J Cancer; 2004 Jul; 40(10):1517-21. PubMed ID: 15196535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
    Briasoulis E; Pentheroudakis G; Karavasilis V; Tzamakou E; Rammou D; Pavlidis N
    Ann Oncol; 2004 Oct; 15(10):1566-73. PubMed ID: 15367419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
    Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
    Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
    Caponigro F; Comella P; Rivellini F; Avallone A; Budillon A; Di Gennaro E; Mozzillo N; Ionna F; De Rosa V; Manzione L; Comella G
    Ann Oncol; 2000 May; 11(5):575-80. PubMed ID: 10907951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
    Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors.
    Gonçalves A; Braud AC; Viret F; Genre D; Gravis G; Tarpin C; Giovannini M; Maraninchi D; Viens P
    Anticancer Res; 2003; 23(4):3543-8. PubMed ID: 12926104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
    Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
    Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
    Gogas H; Papadimitriou C; Kalofonos HP; Bafaloukos D; Fountzilas G; Tsavdaridis D; Anagnostopoulos A; Onyenadum A; Papakostas P; Economopoulos T; Christodoulou C; Kosmidis P; Markopoulos C
    Ann Oncol; 2002 Nov; 13(11):1737-42. PubMed ID: 12419745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.